Plenty of good news is on the horizon. The first U.S. sales will be welcome, but my real excitement will come with a measurable manufacturing, sales, delivery, and surgeon-adoption pipeline expands over the next 12 months. That will get analysts excited. I added more shares yesterday in the low $1.40s because, although stock prices are supposed to be forward-looking, as yet I still don’t see this inbound good news priced in.
Without the DT#2 distractions, OCC would probably already be trading at $2.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)